Literature DB >> 15743186

N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.

Remo Guerrini1, Girolamo Caló, David G Lambert, Giacomo Carrá, Marika Arduin, Tim A Barnes, John McDonald, Daniela Rizzi, Claudio Trapella, Erika Marzola, David J Rowbotham, Domenico Regoli, Severo Salvadori.   

Abstract

Previous structure-activity studies on nociceptin/orphanin FQ (N/OFQ) identified [Phe(1)Psi(CH(2)NH)Gly(2)]N/OFQ(1-13)-NH(2) and [Nphe(1)]N/OFQ(1-13)-NH(2) as a N/OFQ peptide receptor (NOP) partial agonist and pure antagonist, respectively. The addition of fluorine to the Phe(4) or the insertion of a further pair of basic amino acids Arg(14)-Lys(15) generate potent agonists. On the basis of these findings, we combined in the N/OFQ-NH(2) template the chemical modifications Arg(14)-Lys(15) and (pF)Phe(4) that increase the agonist potency with those conferring partial agonist (Phe(1)Psi(CH(2)NH)Gly(2)) or pure antagonist (Nphe(1)) properties. Twelve peptides were synthesized and pharmacologically evaluated in Chinese hamster ovary cells expressing the human recombinant NOP and in electrically stimulated mouse vas deferens and guinea pig ileum assays. All peptides behaved as NOP ligands; the chemical modifications Arg(14)-Lys(15) and (pF)Phe(4) increased ligand affinity/potency. Peptides with the normal Phe(1)-Gly(2) peptide bond behaved as full agonists, and those with the Phe(1)Psi(CH(2)NH)Gly(2) modification behaved as partial agonists, while those with the Nphe(1) modification behaved as partial agonists or pure antagonists depending on the presence or absence of the (pF)Phe(4) modification, respectively. The full agonist [(pF)Phe(4),Arg(14),Lys(15)]N/OFQ-NH(2), the partial agonist [Phe(1)Psi(CH(2)NH)Gly(2),(pF)Phe(4),Arg(14),Lys(15)]N/OFQ-NH(2), and the pure antagonist [Nphe(1),Arg(14),Lys(15)]N/OFQ-NH(2) represent the most potent peptide ligands for NOP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15743186     DOI: 10.1021/jm040106v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.

Authors:  Massimo Ibba; Masato Kitayama; John McDonald; Girolamo Calo; Remo Guerrini; Judit Farkas; Geza Toth; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-21       Impact factor: 3.000

Review 2.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

3.  Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats.

Authors:  Giovanni Vitale; Valentina Ruggieri; Monica Filaferro; Claudio Frigeri; Silvia Alboni; Fabio Tascedda; Nicoletta Brunello; Remo Guerrini; Carlo Cifani; Maurizio Massi
Journal:  Psychopharmacology (Berl)       Date:  2009-08-27       Impact factor: 4.530

4.  Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).

Authors:  Mark F Bird; Maria Camilla Cerlesi; Mark Brown; Davide Malfacini; Vanessa Vezzi; Paola Molinari; Laura Micheli; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Remo Guerrini; Girolamo Calò; David G Lambert
Journal:  PLoS One       Date:  2016-06-07       Impact factor: 3.240

5.  In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue c[Cys(7,10)]N/OFQ(1-13)NH (2).

Authors:  M Kitayama; J McDonald; T A Barnes; G Calo'; R Guerrini; D J Rowbotham; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-28       Impact factor: 3.195

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.